

Press release

July 18, 2025

Wacker Chemie AG
Corporate Communications
Gisela-Stein-Strasse 1
81671 Munich, Germany
www.wacker.com

.....

WACKER publishes preliminary Q2 figures and adjusts annual outlook

- Preliminary sales figure for Q2 2025 totals €1.4 billion, EBITDA of €114 million in line with market expectations
- Full year outlook revised: sales now expected to total between €5.5 billion and €5.9 billion (previous guidance: €6.1 billion to €6.4 billion), EBITDA predicted to come to between €500 million and €700 million (previous guidance: €700 million to €900 million)
- CEO Christian Hartel: “The main reason behind our lower expectations is the ongoing macroeconomic and geopolitical uncertainty, which is resulting in weak demand among our customers in numerous segments. There are no signs of a recovery so far.”

Munich – Today, Wacker Chemie AG published its preliminary figures for Q2 2025. The company reported Group sales of €1.41 billion for the second quarter (Q2 2024: €1.47 billion). EBITDA is reported to have totaled €114 million (Q2 2024: €155 million).¹ These figures are in line with current average market expectations, which put Group sales at €1.45 billion and EBITDA at €119 million (source: Vara Research, July 16, 2025).

WACKER also revised its outlook for 2025 on the basis of current estimates. Its Group sales guidance is now in the range of €5.5 billion to €5.9 billion (previous guidance: €6.1 billion to €6.4 billion). Full-year EBITDA is now expected to reach between €500 million and €700 million (previous guidance: €700 million to €900

¹ Wacker Chemie AG made a change to its accounting policies effective June 30. The result from investments in joint ventures and associates and other investment income are now reported under the financial result, meaning that they are no longer part of EBITDA or EBIT. In the second quarter of 2025, this reclassification leads to an increase in EBITDA of €1 million (Q2 2024: decrease of €5 million). Further details can be found in the half-yearly report, which will be published on July 31.

million). The current average market expectations put Group sales at €5.8 billion and EBITDA at around €670 million (source: Vara Research, July 16, 2025). The company now expects to report a more or less balanced net cash flow (previous guidance: positive, substantially higher than in the previous year).

“The main reason behind our lower expectations is the ongoing macroeconomic and geopolitical uncertainty, which is resulting in weak demand among our customers in numerous segments. There are no signs of a recovery so far,” said Group President & CEO Christian Hartel. The adjustment is also prompted by the unfavorable development in EUR/USD exchange rates since the beginning of the second quarter and the expectation that the current exchange rate level will remain unchanged. As far as polysilicon is concerned, WACKER had also expected the trade policy related uncertainties in the US market for solar polysilicon to be resolved over the course of the year, allowing demand to recover. This development has so far not materialized.

In response to the situation, the company has initiated a comprehensive package of measures to save costs and improve cash flow.

Business divisions

The preliminary figures put sales in the Silicones division at €713 million in the second quarter, a decrease of 1 percent year over year. EBITDA for the second quarter is expected to come to €104 million as against €90 million a year earlier. An insurance compensation had a low double-digit million positive impact. For the full year, WACKER now expects sales and EBITDA for the division to be on a par with the previous year's level (previous guidance: 10 percent increase in sales, EBITDA margin up slightly year over year).

According to the preliminary figures, the Polymers division generated sales of €363 million in the second quarter, down 7 percent year over year. EBITDA is likely to have totaled €40 million (Q2 2024: €59 million). For the full year, WACKER now expects to see a low single-digit percentage decline in sales for the division (previous guidance: increase in sales in the low-single-digit percentage range). The EBITDA margin is still expected to remain at the previous year's level.

Based on the preliminary figures, the Biosolutions division generated sales of €87 million in the second quarter, down by 11 percent compared to the same period last year. EBITDA is likely to have totaled €5 million as against €1 million a year earlier. For the full year, WACKER now expects the division's sales match last year's level (previous guidance: sales of €400 million). The EBITDA margin is expected at the previous year's level (previous guidance: EBITDA margin slightly above the previous year's level).

The preliminary figures report sales of €218 million in the Polysilicon division in the second quarter, down by 6 percent compared to the previous year. EBITDA for the second quarter is expected to have come to €34 million as against €55 million a year earlier. For the full year, WACKER expects sales in the division to remain at the previous year's level (previous guidance: €1.0 billion to €1.3 billion). EBITDA is predicted to be around €100 million (previous guidance: €100 million to €250 million).

WACKER will publish its report for the first half of 2025 on July 31, 2025.

Additional information

Manuela Dollinger

Media Relations

Tel. +49 89 6279-1629

Manuela.Dollinger@wacker.com

The company in brief

WACKER is a global company with state-of-the-art specialty chemical products found in countless everyday items, with applications ranging from tile adhesives to computer chips. The company has a global network of 27 production sites, 21 technical competence centers and 46 sales offices. With around 16,600 employees, WACKER generated annual sales of around €5.7 billion in fiscal 2024.

WACKER operates through four business divisions. The chemical divisions Silicones and Polymers supply products (silicones, polymeric binders) for the automotive, construction, chemical, consumer goods and medical technology industries. Biosolutions, the life sciences division, specializes in bioengineered products such as biopharmaceuticals and food additives. Polysilicon produces hyperpure polysilicon for the semiconductor and photovoltaic industries.

www.wacker.com
